Citations

Clear

3030 citation(s) found for "Susan, M".

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
Nowakowski, Grzegorz S. , Maurer, Matthew J. , Ansell, Stephen M. , Macon, William R. , Ristow, Kay M., Allmer, Cristine, Cerhan, James R. , Habermann, Thomas M. , Slager, Susan L. , Witzig, Thomas E. , Maurer, Matthew , Cerhan, James R

Mayo Clinic

Journal of Clinical Oncology | December 14, 2009 | Volume: 28 | Issue: 3 | Pages: 412-417

10.1200/jco.2009.23.4245 | PMID 20008638 Get It

Purpose Statins have antilymphoma properties but have also been shown to inhibit the binding of rituximab to the CD20 antigen, resulting in reduced antitumor activity of rituximab in vitro. The clinical impact of statin use on the outcome of lymphoma patients treated with a rituximab-containing regimen is unknown. Patients and Methods Consecutive patients with newly diagnosed, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were enrolled onto a registry and observed prospectively. The impact of statin use on patients' outcomes was analyzed. Results Two hundred twenty-eight patients with DLBCL and 293 patients with FL were enrolled from September 2002 through June 2007; 21% of patients with DLBCL and 19% of patients with FL were on statins at diagnosis, and 20% and 17% remained on statins during lymphoma treatment, respectively. All patients with DLBCL and 39% of patients with FL received initial therapy containing rituximab. The median follow-up time was 47 months (range, 13 to 80 months). Statin use had no impact on the overall response rate (P = .67), overall survival (P = .76), or event-free survival (EFS) in patients with DLBCL (hazard ratio [HR] = 0.85; 95% CI, 0.43 to 1.68). Statin use at diagnosis was associated with improved EFS in patients with FL (HR = 0.45; 95% CI, 0.26 to 0.77), including subgroups treated with rituximab or a rituximab-containing regimen (HR = 0.38; 95% CI, 0.14 to 1.07) and patients who were observed only (HR = 0.38; 95% CI, 0.17 to 0.84). Conclusion The concurrent use of statins during the treatment of patients with DLBCL and FL in the rituximab era did not adversely affect outcome. The apparent benefit of statin therapy on FL outcome requires further studies.
Childhood Exposure to Secondhand Smoke and Functional Mannose Binding Lectin Polymorphisms Are Associated with Increased Lung Cancer Risk
Olivo‐Marston, Susan , Mechanic, Leah E. , Bowman, Elise D. , Loffredo, Christopher A. , Alberg, Anthony J. , Caporaso, Neil E. , Shields, Peter G. , Jiang, Ruoxiang , Cunningham, Julie M. , Jen, Jin , Harris, Curtis C. , Yang, Ping , Pine, Sharon R. , Chanock, Stephen Jacob , Wu, Yanhong

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 3, 2009 | Volume: 18 | Issue: 12 | Pages: 3375-3383

10.1158/1055-9965.epi-09-0986 | PMID 19959685 Get It

Abstract Background: Exposure to secondhand smoke during adulthood has detrimental health effects, including increased lung cancer risk. Compared with adults, children may be more susceptible to secondhand smoke. This susceptibility may be exacerbated by alterations in inherited genetic variants of innate immunity genes. We hypothesized a positive association between childhood secondhand smoke exposure and lung cancer risk that would be modified by genetic polymorphisms in the mannose binding lectin-2 (MBL2) gene resulting in well-known functional changes in innate immunity. Methods: Childhood secondhand smoke exposure and lung cancer risk was assessed among men and women in the ongoing National Cancer Institute-Maryland Lung Cancer (NCI-MD) study, which included 624 cases and 348 controls. Secondhand smoke history was collected via in-person interviews. DNA was used for genotyping the MBL2 gene. To replicate, we used an independent case-control study from Mayo Clinic consisting of 461 never smokers, made up of 172 cases and 289 controls. All statistical tests were two-sided. Results: In the NCI-MD study, secondhand smoke exposure during childhood was associated with increased lung cancer risk among never smokers [odds ratio (OR), 2.25; 95% confidence interval (95% CI), 1.04-4.90]. This was confirmed in the Mayo study (OR, 1.47; 95% CI, 1.00-2.15). A functional MBL2 haplotype associated with high circulating levels of MBL and increased MBL2 activity was associated with increased lung cancer risk among those exposed to childhood secondhand smoke in both the NCI-MD and Mayo studies (OR, 2.52; 95% CI, 1.13-5.60, and OR, 2.78; 95% CI, 1.18-3.85, respectively). Conclusions: Secondhand smoke exposure during childhood is associated with increased lung cancer risk among never smokers, particularly among those possessing a haplotype corresponding to a known overactive complement pathway of the innate immune system. (Cancer Epidemiol Biomarkers Prev 2009;18(12):3375–83)
Consensus Statement on the Terminology and Classification of Central Neck Dissection for Thyroid Cancer
Carty, Sally E. , Cooper, David S. , Doherty, Gerard M. , Duh, Quan‐Yang , Kloos, Richard T. , Mandel, Susan J., Stack, Brendan C. , Steward, David L. , Terris, David J. , Thompson, Geoffrey B. , Tuttle, R. Michael , Udelsman, Robert, Randolph, Gregory William , Tufano, Ralph Patrick , Kloos, Richard T

Mayo Clinic

Thyroid | October 27, 2009 | Volume: 19 | Issue: 11 | Pages: 1153-1158

10.1089/thy.2009.0159 | PMID 19860578 Get It

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Cooper, David S. , Doherty, Gerard M. , Haugen, Bryan R. , Kloos, Richard T. , Lee, Stephanie L. , Mandel, Susan J., Mazzaferri, Ernest L. , McIver, Bryan, Pacini, Furio , Schlumberger, Martin , Sherman, Steven I. , Steward, David L. , Tuttle, R. Michael , Kloos, Richard T , Sherman, Steven I

Mayo Clinic

Thyroid | October 27, 2009 | Volume: 19 | Issue: 11 | Pages: 1167-1214

10.1089/thy.2009.0110 | PMID 19860577 Get It

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
Marks, David I. , Paietta, Elisabeth , Moorman, Anthony V. , Richards, Susan , Buck, Georgina , Dewald, Gordon W., Ferrando, Adolfo A. , Goldstone, Anthony H., Ketterling, Rhett P. , Litzow, Mark R. , Luger, Selina M. , McMillan, Andrew , Mansour, Marc R. , Rowe, Jacob M. , Tallman, Martin S. , Fielding, Adele K. , Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

Blood | October 15, 2009 | Volume: 114 | Issue: 25 | Pages: 5136-5145

10.1182/blood-2009-08-231217 | PMID 19828704 Get It

AbstractThe biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, χ2, P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Frye, Robin, Turner, Maria L., Allen, Steven L. , Kirschbaum, Mark, Zain, Jasmine , Prince, H. Miles , Leonard, John P. , Geskin, Larisa J. , Reeder, Craig B. , Joske, David, Figg, William D. , Gardner, Erin R., Steinberg, Seth M. , Stetler‐Stevenson, Maryalice , Lade, Stephen , Fojo, Antonio Tito, Bates, Susan E. , Piekarz, Richard , Wright, John Joseph , Jaffe, Elaine S. , Prince, H Miles , Bates, Susan E

Mayo Clinic

Journal of Clinical Oncology | October 14, 2009 | Volume: 27 | Issue: 32 | Pages: 5410-5417

10.1200/jco.2008.21.6150 | PMID 19826128 Get It

Purpose Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. Patients and Methods The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sézary syndrome, who had received no more than two prior cytotoxic regimens. There were no limits on other types of therapy. Subsequently, the protocol was expanded to enroll patients who had received more than two prior cytotoxic regimens. Results Twenty-seven patients were enrolled onto the first cohort, and a total of 71 patients are included in this analysis. These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41). Toxicities included nausea, vomiting, fatigue, and transient thrombocytopenia and granulocytopenia. Pharmacokinetics were evaluated with the first administration of romidepsin. Complete responses were observed in four patients, and partial responses were observed in 20 patients for an overall response rate of 34% (95% CI, 23% to 46%). The median duration of response was 13.7 months. Conclusion The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Liu, Pengyuan , Wen, Weidong, James, Michael A. , Wang, Yian , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Yang, Ping , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Lee, Juwon , Seminara, Daniela, Anderson, Marshall W., Liu, Yan , Amos, Christopher I. , Andrade, Mariza de , Minna, John Dorrance , You, Ming , Wilson, Richard K , Pinney, Susan M

Mayo Clinic

Cancer Research | September 29, 2009 | Volume: 69 | Issue: 19 | Pages: 7844-7850

10.1158/0008-5472.can-09-1833 | PMID 19789337 Get It

Abstract Recent genome-wide association studies have linked the chromosome 15q24-25.1 locus to nicotine addiction and lung cancer susceptibility. To refine the 15q24-25.1 locus, we performed a haplotype-based association analysis of 194 familial lung cases and 219 cancer-free controls from the Genetic Epidemiology of Lung Cancer Consortium (GELCC) collection, and used proliferation and apoptosis analyses to determine which gene(s) in the 15q24-25.1 locus mediates effects on lung cancer cell growth in vitro. We identified two distinct subregions, hapL (P = 3.20 × 10−6) and hapN (P = 1.51 × 10−6), which were significantly associated with familial lung cancer. hapL encompasses IREB2, LOC123688, and PSMA4, and hapN encompasses the three nicotinic acetylcholine receptor subunit genes CHRNA5, CHRNA3, and CHRNB4. Examination of the genes around hapL revealed that PSMA4 plays a role in promoting cancer cell proliferation. PSMA4 mRNA levels were increased in lung tumors compared with normal lung tissues. Down-regulation of PSMA4 expression decreased proteasome activity and induced apoptosis. Proteasome dysfunction leads to many diseases including cancer, and drugs that inhibit proteasome activity show promise as a form of cancer treatment. Genes around hapN were also investigated, but did not show any direct effect on lung cancer cell proliferation. We concluded that PSMA4 is a strong candidate mediator of lung cancer cell growth, and may directly affect lung cancer susceptibility through its modulation of cell proliferation and apoptosis. [Cancer Res 2009;69(19):7844–50]
High incidence of profound biotinidase deficiency detected in newborn screening blood spots in the Somalian population in Minnesota
Sarafoglou, Kyriakie , Bentler, Kristi, Gaviglio, A., Redlinger‐Grosse, Krista , Anderson, Carolyn S., McCann, Mark, Bloom, Beth Ann, Babovic‐Vuksanovic, Dusica , Gavrilov, Dimitar , Berry, Susan A. , Gaviglio, Amy , Gaviglio, A.

Mayo Clinic

Journal of Inherited Metabolic Disease | September 14, 2009 | Volume: 32 | Issue: S1 | Pages: 169-173

10.1007/s10545-009-1135-7 | PMID 19757147 Get It

SummaryNewborns identified with profound biotinidase deficiency (BTD) by the Minnesota Newborn Screening Program (MN NBS) between 1 October 2004 and 30 May 2008 were all from new immigrant groups. Thirty‐three positive cases of BTD were identified out of 264 727 infants screened by the Wolf colorimetric system during the period of this study by MN NBS. Five cases of profound BTD (0.1 to <0.6 nmol/min per ml) and 26 cases of partial BTD (0.9 to 2.3 nmol/min per ml) were later confirmed through measurement of serum biotinidase activity. The incidence of combined partial and profound BTD of 1/8540 and that of profound BTD of 1/52 945 in Minnesota are unusually high in comparison with the reported worldwide numbers of 1/61 067 for combined BTD and 1/137 401 for profound BTD. Four out of the 5 cases of profound BTD ascertained in the MN NBS cohort were of Somali ethnic background, and the remaining case was of Asian (Pakistani/Indian) ethnic background. All four Somali patients have the P497S mutation, with one of the four being homozygous for the mutation. The three compound heterozygotes all have a novel mutation (P142T) and two of them have another change (Y428Y) that has never been described. Within the last two decades, Minnesota has become home to an estimated 40 000 Somali immigrants and their children (<1% of the total Minnesota population). New population demographics prompt careful analysis of case cohorts to identify specific groups at risk for rare inborn errors of metabolism.
Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer
Cicek, Mine , Achenbach, Sara J., French, Amy J. , Blair, Hilary, Fink, Stephanie, Foster, Nathan R. , Kabat, Brian, Halling, Kevin C. , Cunningham, Julie M. , Cerhan, James R. , Jenkins, Robert B. , Boardman, Lisa A., Petersen, Gloria M. , Sargent, Daniel J. , Thibodeau, Stephen N. , Slager, Susan L. , Boardman, Lisa A., Alberts, Steven R. , Limburg, Paul J. , Sargent, Daniel J , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2009 | Volume: 18 | Issue: 9 | Pages: 2492-2500

10.1158/1055-9965.epi-09-0362 | PMID 19690179 Get It

Abstract Multiple genome-wide association studies have identified several susceptibility variants for colon cancer at 8q24. However, the functional roles of these variants have yet to be elucidated. Here, we evaluated the potential role of these markers in tumor progression and examined association with commonly observed structural abnormalities in this region, c-MYC amplification and chromosome fragility at FRA8C and FRA8D. We first replicated the previously reported association by testing 1,178 cases and 1,009 clinic-based controls with eight markers localized to three specific regions at 8q24. We observed significant associations with colon cancer risk with markers rs13254738 (ordinal odds ratio, 0.82; 95% confidence interval, 0.072-0.94; Ptrend = 0.0037) and rs6983267 (ordinal odds ratio, 1.17; 95% confidence interval, 1.03-1.32, Ptrend = 0.013). Survival analysis was done using a separate set of 460 cases to evaluate the clinical significance of these markers. Overall, univariate analysis did not detect survival differences for any of the markers. We also tested a subset of the 460 cases (n = 380) for structural abnormalities at or near the c-MYC locus using fluorescence in situ hybridization analysis. Furthermore, we evaluated a small number of cases homozygous for the rs6983267 alleles to test for differences in fragile site induction. None of the 8q markers correlated with amplification at the c-MYC locus as detected by fluorescence in situ hybridization, and no clear pattern of breakage was observed at the FRA8C and FRA8D sites. In this study, we confirm the association for several single nucleotide polymorphisms at 8q24 in colon cancer but have not detected any structural role relating to c-MYC amplification or chromosomal fragility. Finally, these risk alleles do not seem to be associated with survival. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2492–500)
Neutrophilia Predicts Death and Heart Failure After Myocardial Infarction
Arruda‐Olson, Adelaide M. , Reeder, Guy S., Bell, Malcolm R. , Weston, Susan A., Roger, Véronique L.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 1, 2009 | Volume: 2 | Issue: 6 | Pages: 656-662

10.1161/circoutcomes.108.831024 | PMID 20031905 Get It

Background— The relationship between neutrophils and outcomes post–myocardial infarction (MI) is not completely characterized. We examined the associations of neutrophil count with mortality and post-MI heart failure (HF) and their incremental value for risk discrimination in the community. Methods and Results— MI was diagnosed with cardiac pain, biomarkers, and Minnesota coding of the ECG. Neutrophil count at presentation, reported as counts ×10 9 /L, was categorized by tertiles (lower tertile, <5.7; middle tertile, 5.7 to 8.5; upper tertile, >8.5). From 1979 to 2002, 2047 incident MIs occurred in Olmsted County, Minn (mean age, 68±14 years; 44% women). Median (25th to 75th percentile) neutrophil count was 7.0 (5.1 to 9.5). Within 3 years post-MI, 577 patients died, and 770 developed HF. Overall survival and survival free of HF decreased with increased neutrophil tertile ( P <0.001). Compared with the lower tertile, the age and sex adjusted hazard ratio for death was 1.44 (95% CI, 1.14 to 1.81) for the middle tertile and 2.60 (95% CI, 2.10 to 3.22) for the upper tertile ( P <0.001). Similarly, for HF, the hazard ratio was 1.32 (95% CI, 1.09 to 1.59) for the middle and 2.12 (95% CI, 1.77 to 2.53) for the upper tertile ( P <0.001). These associations persisted after adjustment for risk factors, comorbidities, Killip class, revascularization, and ejection fraction. Neutrophil count improved risk discrimination as indicated by increases in the area under the receiver operating characteristic curves (all P <0.05) and by the integrated discrimination improvement analysis (all P <0.001). Conclusions— In the community, the neutrophil count was strongly and independently associated with death and HF post-MI and improved risk discrimination over traditional predictors.